Therapeutic RNA 5' and 3' End Caps for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing synthetic mRNAs are expensive and difficult to control, limiting the efficient production of RNAs with improved stability and protein expression, especially for clinical applications like CRISPR genome editing.
Innovation Solution
Development of nucleic acid molecules with modifications at the 5′-end, 3′-end, or both, incorporating cap structures based on guanosine or purine, which enhance protein expression and stability, and can be produced using enzymatic or chemical synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzymatic synthesis is used to produce synthetic mRNAs with 5′-cap and 3′-end modifications, then the RNA stability and protein expression are improved, but the production cost increases and the process becomes difficult to control
Solution Approach 1:
The patent divides the RNA modification process into separate modules: 5′-end capping with cap structures (cap 0, cap 1, cap 2) and 3′-end modifications (poly A tail, modified bases). This segmentation allows independent optimization of each modification type and enables standardized production protocols that improve both reliability and ease of manufacture.
Solution Approach 2:
The patent systematically varies parameters including cap structure type (cap 0 with N7-methylguanosine, cap 1 with additional methylations, cap 2 with further modifications), 3′-end tail length, and specific modification positions to achieve optimal RNA stability and expression while maintaining manufacturability through defined parameter sets.
2Stability of the object's composition
If natural mRNA structures with 5′-cap and 3′-poly A tail are used, then RNA stability and translation are improved, but the synthesis process becomes complex and expensive
Solution Approach 1:
The patent creates simplified copies of natural mRNA structures using chemically synthesized cap analogs and standardized modification kits. These copies replicate the functional stability and translation efficiency of natural mRNAs while using simpler, more controllable synthesis procedures that reduce process complexity and cost.
Solution Approach 2:
The patent employs composite RNA structures combining conventional nucleotides with modified cap structures (N7-methylguanosine, N1-methylguanosine, N2-methylguanosine) and 3′-end modifications. This composite approach maintains biological functionality while enabling controlled synthesis through defined compositional rules.
Data Source
AI summary
The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.